NASDAQ · CTOR
Healthcare · Drug Manufacturers - General
$0.78
Down-$0.01 (-1.86%)
Updated Aug 30, 2026, 11:59 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CTOR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CTOR.
CTOR research
Company profile and research snapshot.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2025 | Maxim Group | Buy | — |
| May 23, 2025 | Maxim Group | Hold | — |
| Nov 27, 2024 | Maxim Group | Buy | — |
| Aug 13, 2024 | EF Hutton | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494
Yahoo · Aug 12, 2026
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., J.D., as an additional independent director, effective August 10, 2026. Following a unanimous vote of approval by the Board, the appointment expands the Company's Board of Directors to nine members.
Yahoo · Aug 5, 2026
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supporting the product's commercial launch.
Benzinga · Feb 13, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTOR.
